The S&P 500 lost 31% in March.
The IPO market saw a huge slump in the ensuing months.
There was little confidence in the public market.
But certain players in the health sector did not hurt the same.
In fact, tech and health stocks seemed more stable with a work-from-home trend and a push for coronavirus vaccines.
While these sectors got a lift from this year's events, they didn't need it.
There will always be companies innovating in tech and health, despite any lockdown scenario.
Grail is one of those companies.
That's why, in a year of scant IPOs, this innovative biotech is one of a handful that have come out announcing their IPO underway.
Start the conversation